The US Food and Drug Administration has taken action to restrict the unlawful entry of xylazine-active pharmaceutical ingredients and finished dosage form drug products into the US, the agency said Tuesday.
The FDA aims to prevent the drug from entering the US market for purposes such as illicitly manufactured fentanyl but also keep it available for its legitimate uses by veterinarians, the FDA said.
The import alert allows FDA staff to detain xylazine shipments if it appears to be in violation of the law, and shipments are subject to heightened scrutiny, according to the FDA.
This story was produced by ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.